Clinical trials: Breast Cancer Recurrent, open to volunteers
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Triple-negative Breast Cancer
Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
Breast cancer is one of the most common cancers among women. One in eight women in France will develop breast cancer during their lifetime (Inca).
- Trial name
- EPPIL (NCT07458204)
- Testing
- LVB infiltration
- Where
- France
- Volunteers
- 760 people
- Sponsor
- Institut Jean-Godinot
Breast Neoplasms
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC)…
- Trial name
- NCT06926868
- Testing
- Iza-bren, Nab-paclitaxel, Paclitaxel
- Where
- 295 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS)…
- Trial name
- OFSET (NCT05879926)
- Testing
- Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
- Where
- 1,261 sites in United States, Canada and 6 more
- Volunteers
- 3,960 people
- Sponsor
- NRG Oncology
Breast Cancer, Locally Recurrent Breast Cancer
Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients
Sentinel lymph node biopsy (SLNB) is essential for staging and treatment planning in early breast cancer patients. As a less invasive procedure, it has replaced axillary lymph node dissection (ALND) by reducing complications and…
- Conditions
- Breast Cancer, Locally Recurrent Breast Cancer, Sentinel Lymph Node Biopsy (SLNB), Reoperation
- Trial name
- NCT06780748
- Testing
- Identification rate of sentinel lymph node
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Triple Negative Breast Cancer
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
TNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour…
- Trial name
- ADAPT-TN-III (NCT06081244)
- Testing
- Sacituzumab govitecan, Pembrolizumab
- Where
- 43 sites in Germany
- Volunteers
- 348 people
- Sponsor
- Women's Cancer Study Group GmbH
Advanced Breast Cancer
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure still remains to be established. We would like to investigate the efficacy and safety of combination chemotherapy of eribulin and…
- Trial name
- ESPERO (NCT05530057)
- Testing
- Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Hospital
Stomatitis
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal…
- Trial name
- TROPION-SWISH (NCT07357597)
- Testing
- Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
- Where
- 41 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation
Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1/2…
- Conditions
- Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation, Fear of Cancer Recurrence
- Trial name
- CBT-FCRBRCA1/2 (NCT06817694)
- Testing
- Cognitive-behavioral group therapy
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- CHU de Quebec-Universite Laval
Recurrent Breast Carcinoma, Ipsilateral Recurrence
Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial
Over the past decades, interest in second breast-conserving therapy (BCT) has increased due to, among others, advancements in radiotherapy techniques.
- Trial name
- REPEAT (NCT06640881)
- Testing
- ablative single-dose PBI
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Amsterdam UMC, location VUmc
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04529044
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
Breast Cancer Proteomics and Molecular Heterogeneity
Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor…
- Trial name
- NCT01840293
- Where
- 6 sites in Ireland
- Volunteers
- 1,780 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer, Breast Cancer Female
Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer
Surveillance and aftercare for curatively treated primary breast cancer patients is currently mostly 'one-size-fits-all', but can be personalized based on patients' risk of recurrence (depending on patient-, tumor- and…
- Conditions
- Breast Cancer, Breast Cancer Female, Survivorship
- Trial name
- NABOR (NCT05975437)
- Testing
- personalized surveillance plans (PSP) and personalized aftercare plans (PAP)
- Where
- 10 sites in Netherlands
- Volunteers
- 1,040 people
- Sponsor
- Comprehensive Cancer Centre The Netherlands
Breast Cancer
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative…
- Trial name
- NCT07164976
- Testing
- Ribociclib 400mg, Ribociclib 600mg
- Where
- Japan
- Volunteers
- 86 people
- Sponsor
- Nagoya City University
Breast Cancer Recurrent
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
- Trial name
- TOWARDS-II (NCT05464082)
- Testing
- Functional Precision Oncology
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Breast Cancer, Breast Neoplasm
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
- Trial name
- NCT06075810
- Testing
- MBQ-167
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 48 people
- Sponsor
- MBQ Pharma
Recurrent Breast Carcinoma
Study on Recurrent Breast Cancer and Repeated Radiation Therapy
This study explores whether recurrent breast cancer can be safely treated with breast-conserving surgery and repeated radiation therapy in cases where patients have previously undergone radiation.
- Trial name
- RAY-no-BAN (NCT06704659)
- Testing
- Breast conserving surgey and radiotherapy, Mastectomy
- Where
- 2 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Turku University Hospital
Breast Carcinoma
Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence .
the study will discuss the concordance of the biology of primary breast carcinoma and the biology of recurrence. The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center…
- Trial name
- NCT07275203
- Testing
- No intervention
- Volunteers
- 200 people
- Sponsor
- Sohag University
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with…
- Conditions
- PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
- Trial name
- ReDiscover-2 (NCT06982521)
- Testing
- Zovegalisib, Capivasertib, Fulvestrant
- Where
- 243 sites in United States, Argentina and 25 more
- Volunteers
- 540 people
- Sponsor
- Relay Therapeutics, Inc.
Local Neoplasm Recurrence, Distantly Metastatic Malignant Neoplasm
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer.
- Conditions
- Local Neoplasm Recurrence, Distantly Metastatic Malignant Neoplasm, Death, Fibrosis Breast
- Trial name
- NCT03646955
- Testing
- No partial breast irradiation
- Where
- 17 sites in Chile, Denmark and 2 more
- Volunteers
- 926 people
- Sponsor
- Danish Breast Cancer Cooperative Group